



Financial Statements

For the Year Ended
December 31, 2016



The Progeria Research Foundation, Inc.

Financial Statements

For the Year Ended December 31, 2016

Table of Contents

Independent Auditors' Report.....	1
Financial Statements:	
Statement of Financial Position.....	2
Statement of Activities.....	3
Statement of Functional Expenses.....	4
Statement of Cash Flows.....	5
Notes to Financial Statements.....	6-13

Independent Auditors' Report

To the Board of Directors
The Progeria Research Foundation, Inc.
Peabody, Massachusetts

We have audited the accompanying financial statements of The Progeria Research Foundation, Inc. (a nonprofit organization), which comprise the statement of financial position as of December 31, 2016 and the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of The Progeria Research Foundation, Inc. as of December 31, 2016 and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

LitmanGerson Associates, LLP

Woburn, Massachusetts
August 16, 2017

The Progeria Research Foundation, Inc.

Statement of Financial Position

December 31, 2016

Assets

Current assets:

Cash and cash equivalents	\$	604,044
Contributions receivable, net		402,236
Investments		3,256,188
Prepaid expenses		74,726
Total current assets		<u>4,337,194</u>

Property and equipment, net

20,015

Other assets:

Contributions receivable - noncurrent (\$334,000 face amount, non-interest bearing, less unamortized discount of \$12,072)		321,928
Patents, net		97,735
Security deposit		3,000
Total other assets		<u>422,663</u>

Total assets

\$ 4,779,872

Liabilities and Net Assets

Current liabilities:

Accounts payable and other current liabilities	\$	385,355
Total current liabilities		<u>385,355</u>

Net assets:

Unrestricted		3,659,339
Temporarily restricted		735,178
Total net assets		<u>4,394,517</u>

Total liabilities and net assets

\$ 4,779,872

The accompanying notes are an integral part of the financial statements.

The Progeria Research Foundation, Inc.

Statement of Activities

For the Year Ended December 31, 2016

	Unrestricted	Temporarily Restricted	Total
Support and Revenue			
Contributions	\$ 1,711,403	\$ 710,178	\$ 2,421,581
In-kind contributions	173,827	-	173,827
Investment income, net	50,942	-	50,942
Government grants	35,000	-	35,000
Net assets released from restrictions for timing	105,880	(105,880)	-
	<u>2,077,052</u>	<u>604,298</u>	<u>2,681,350</u>
Special events	848,375	-	848,375
Less: costs of direct benefits to donors	(183,399)	-	(183,399)
	<u>664,976</u>	<u>-</u>	<u>664,976</u>
Total support and revenue	<u>2,742,028</u>	<u>604,298</u>	<u>3,346,326</u>
Expenses			
Program services	2,306,894	-	2,306,894
Supporting services	336,447	-	336,447
Fundraising	182,680	-	182,680
Total expenses	<u>2,826,021</u>	<u>-</u>	<u>2,826,021</u>
Change in net assets	(83,993)	604,298	520,305
Net assets at beginning of year	<u>3,743,332</u>	<u>130,880</u>	<u>3,874,212</u>
Net assets at end of year	<u>\$ 3,659,339</u>	<u>\$ 735,178</u>	<u>\$ 4,394,517</u>

The accompanying notes are an integral part of the financial statements.

The Progeria Research Foundation, Inc.

Statement of Functional Expenses

For the Year Ended December 31, 2016

	<u>Program Services</u>	<u>Supporting Services</u>	<u>Fundraising</u>	<u>Total</u>
Compensation:				
Salaries and wages	\$ 257,494	\$ 159,158	\$ 130,752	\$ 547,404
Payroll taxes	23,518	14,588	11,952	50,058
Employee benefits	12,719	7,157	7,673	27,549
	<u>293,731</u>	<u>180,903</u>	<u>150,377</u>	<u>625,011</u>
Other:				
Research grants and other assistance	725,929	-	-	725,929
Drug trial	639,156	-	-	639,156
Professional fees	138,293	53,453	-	191,746
Cell and tissue bank	105,743	-	-	105,743
Diagnostic testing	104,639	-	-	104,639
Scientific workshop	102,385	-	-	102,385
Medical and research database	99,358	-	-	99,358
Printing	46,321	2,782	-	49,103
Occupancy	7,200	28,800	-	36,000
Communications	17,820	7,423	-	25,243
Postage and shipping	14,371	5,887	9,329	29,587
Office expenses	-	16,364	-	16,364
Computer expenses	-	16,338	-	16,338
Consulting	-	-	19,320	19,320
Depreciation and amortization	6,972	6,513	-	13,485
Travel	2,993	501	3,654	7,148
Online processing fees	-	6,530	-	6,530
Utilities	-	4,666	-	4,666
Insurance	-	3,324	-	3,324
Dues and subscriptions	-	2,799	-	2,799
Media expense	1,918	-	-	1,918
Professional development	-	164	-	164
Patient handbooks	65	-	-	65
	<u>2,013,163</u>	<u>155,544</u>	<u>32,303</u>	<u>2,201,010</u>
Total expenses	<u>\$ 2,306,894</u>	<u>\$ 336,447</u>	<u>\$ 182,680</u>	<u>\$ 2,826,021</u>

The accompanying notes are an integral part of the financial statements.

The Progeria Research Foundation, Inc.

Statement of Cash Flows

For the Year Ended December 31, 2016

Cash flows from operating activities:	
Change in net assets	\$ 520,305
Adjustments to reconcile change in net assets to net cash used in operating activities:	
Depreciation and amortization	13,485
Interest and dividends reinvested	(50,830)
Changes in operating assets and liabilities:	
Increase in:	
Contributions receivable	(554,564)
Prepaid expenses	(45,493)
Decrease in:	
Accounts payable and other current liabilities	(48,594)
Net cash used in operating activities	<u>(165,691)</u>
Cash flows from investing activities:	
Proceeds from sales of investments	250,000
Purchases of property and equipment	(12,155)
Payment of patent costs	(6,336)
Net cash provided by investing activities	<u>231,509</u>
Net increase in cash and cash equivalents	65,818
Cash and cash equivalents at beginning of year	<u>538,226</u>
Cash and cash equivalents at end of year	<u><u>\$ 604,044</u></u>
Supplemental disclosures of cash flow information:	
Cash paid during the year for:	
Interest	<u><u>\$ -</u></u>
Income taxes	<u><u>\$ -</u></u>

The accompanying notes are an integral part of the financial statements.

The Progeria Research Foundation, Inc.

Notes to Financial Statements

For the Year Ended December 31, 2016

1. Nature of Business

The Progeria Research Foundation, Inc. (the Organization) is a nonprofit organization established in 1999 in the Commonwealth of Massachusetts to discover treatments and the cure for Hutchinson-Gilford Progeria Syndrome and its aging-related disorders, including heart disease.

2. Summary of Significant Accounting Policies

Basis of Presentation

The financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) to ensure the statements of financial position, activities, functional expenses and cash flows are consistently reported. References to GAAP issued by the FASB in these notes are to the FASB Accounting Standards Codification (ASC).

Basis of Accounting

The Organization's financial statements have been prepared on the accrual basis of accounting. A summary of the significant accounting policies applied in the preparation of the financial statements follows.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Actual results could differ from those estimates.

Financial Statement Presentation

Financial statement presentation follows the recommendations of the FASB ASC Topic No. 958 *Not-for-Profit Entities* (ASC 958). Under ASC 958, the Organization is required to report information regarding its financial position and activities according to three classes of net assets, as follows:

Unrestricted

Unrestricted net assets include amounts that are neither permanently restricted nor temporarily restricted by donor-imposed stipulations.

Temporarily Restricted

Temporarily restricted net assets include amounts resulting from contributions and other inflows of assets whose use by the Organization is limited by donor-imposed stipulations that either expire with the passage of time or can be fulfilled and removed by actions of the Organization pursuant to those stipulations.

Permanently Restricted

Permanently restricted net assets include amounts resulting from contributions and other inflows of assets whose use by the Organization is restricted by donor stipulations that neither expire by the passage of time nor can be fulfilled or otherwise removed by the actions of the Organization. There were no permanently restricted net assets held by the Organization at December 31, 2016.

Cash and Cash Equivalents

For the purposes of the statements of cash flows, the Organization considers all highly liquid instruments with original maturities of three months or less, when purchased, to be cash equivalents.

The Progeria Research Foundation, Inc.

Notes to Financial Statements

For the Year Ended December 31, 2016

2. Summary of Significant Accounting Policies...continued

Contributions Receivable

Contributions receivable are stated at unpaid balances, less an allowance for doubtful accounts. Contributions to be received after one year are discounted at an appropriate discount rate commensurate with the risk involved. Amortization of the discount is recorded as additional contribution revenue in accordance with donor-imposed stipulations, if any, on the contribution. The Organization provides for losses on accounts using the allowance method. The allowance for doubtful accounts is based on experience and other circumstances which may affect the ability of contributors to meet their obligations. Receivables are considered uncollectible if full payments are not received in accordance with the terms of the pledge. At December 31, 2016, the Organization has determined contributions receivable to be fully collectible. Accordingly, no allowance for doubtful accounts was recorded.

Investments

The Organization has adopted FASB ASC Topic No. 958-320 *Accounting for Certain Investments Held by Not-for-Profit Organizations* (ASC 958-320). Under ASC 958-320, investments are reported at fair value. Related interest and dividends are recorded on the accrual basis. Investment income or loss, which consists of interest and dividend income, realized gains and losses, and unrealized gains and losses on those investments, is included in unrestricted revenue in the statement of activities.

Property and Equipment

Property and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line and accelerated methods over estimated useful lives ranging between five and fifteen years. The Organization capitalizes expenditures for property and equipment with a cost in excess of \$1,000. Expenditures for maintenance and repairs are charged to expense as incurred and expenditures which significantly increase values or extend useful lives are capitalized. Upon the disposition of property and equipment, the cost and related accumulated depreciation are eliminated from the accounts and the gain or loss thereon is reflected in the statement of activities.

Patents

Patents are capitalized and amortized on a straight-line basis over their estimated useful life of 17 years. The Organization capitalizes certain costs to maintain, defend and renew patents as incurred and amortizes those costs over the remaining life of the related patent.

Fair Value Measurements

The Organization discloses the fair value of investments (see Note 6) in accordance with FASB ASC Topic No. 820 *Fair Value Measurements* (ASC 820). The framework under ASC 820 provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value.

The Progeria Research Foundation, Inc.

Notes to Financial Statements

For the Year Ended December 31, 2016

2. Summary of Significant Accounting Policies...continued

Fair Value Measurements...continued

The three levels of the fair value hierarchy under ASC 820 are described as follows:

- Level 1 - Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Organization has the ability to access.
- Level 2 - Inputs to the valuation methodology include:
- quoted prices for similar assets or liabilities in active markets;
 - quoted prices for identical or similar assets or liabilities in inactive markets;
 - inputs other than quoted prices that are observable for the asset or liability;
 - inputs that are derived principally from or corroborated by observable market data by correlation or other means.
- Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

Valuation Techniques

Following is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in the methodologies used at December 31, 2016.

Certificates of Deposit

Certificates of deposit are valued at amortized cost plus accrued interest, which approximates fair value, and are classified as Level 2.

Annuity Contract

The annuity contract is reported at contract value, which approximates fair value. Contract value represents contributions made under the agreement, plus earnings, less withdrawals and administrative expenses. As this investment is contract-based, observable prices for identical or similar investments do not exist, and accordingly, the investment is valued using unobservable inputs and is classified as Level 3.

Revenue Recognition

Contributions

Contributions, including unconditional promises to give, are recognized as revenues in the period received or pledged. Conditional promises to give are not recognized until they become unconditional, that is, at the time the conditions on which they depend are substantially met. Contributions of assets other than cash are recorded at their estimated fair value.

Contributions of property and equipment and other long-lived assets are also reported as unrestricted revenue and net assets, unless subject to time restrictions. Absent explicit donor stipulations for the time long-lived assets must be held, expirations of restrictions resulting in reclassification of temporarily restricted net assets as unrestricted net assets are reported when the long-lived assets are placed in service.

The Progeria Research Foundation, Inc.

Notes to Financial Statements

For the Year Ended December 31, 2016

2. Summary of Significant Accounting Policies...continued

Revenue Recognition...continued

Contributions...continued

All contributions are considered to be available for unrestricted use unless specifically restricted by the donor. Amounts received that are designated for future periods or restricted by the donor for specific purposes are reported as temporarily restricted or permanently restricted support depending upon the condition(s) stipulated by the donor. When a restriction expires (that is, when a stipulated time restriction ends or purpose restriction is accomplished), temporarily restricted net assets are reclassified to unrestricted net assets and are reported in the statement of activities as net assets released from restriction. However, if a restriction is fulfilled in the same time period in which the contribution is received, the amount is reported as unrestricted in the year received.

In-Kind Contributions

In-kind contributions are reflected as contributions at their estimated fair value at the date of donation and are reported as unrestricted support unless explicit donor stipulations specify how donated assets must be used. The Organization recognizes the estimated fair value of contributed services if such services meet the following criteria:

- The services received either create or enhance nonfinancial assets, or
- The services received require special skills and are provided by individuals possessing those skills, and the services received would typically need to be purchased if not contributed.

During the year ended December 31, 2016, the Organization received donated accounting, legal, fund-raising and consulting services with estimated fair values of \$173,827, which have been recognized as in-kind contributions and expenses on the accompanying statement of activities.

In addition, many individuals volunteered their time and performed a variety of tasks to assist the Organization in carrying out its mission during the year ended December 31, 2016. These services did not meet the recognition criteria for contributed services. Accordingly, a value for these services has not been reflected in the accompanying statement of activities.

Functional Allocation of Expenses

The Organization allocates its expenses on a functional basis among its program and support services. Expenses that can be identified with a specific program or support service are allocated directly according to their natural expense classification, while other expenses are allocated based on management's systematic and rational policy of estimating the percentage attributable to its program or support service.

Income Taxes

The Organization is a nonprofit organization, which is exempt from income taxes under Section 501(c)(3) of the Internal Revenue Code (IRC), and is a public charity according to Section 509(a)(1) of the IRC. Accordingly, no provision for income taxes has been recorded in the accompanying financial statements.

The Progeria Research Foundation, Inc.

Notes to Financial Statements

For the Year Ended December 31, 2016

2. Summary of Significant Accounting Policies...continued

Income Taxes...continued

The Organization accounts for the uncertainty in income taxes in accordance with the provisions of FASB ASC Topic No. 740 *Income Taxes* (ASC 740), which prescribes a recognition threshold of more likely-than-not, and a measurement attribute for all tax positions taken or expected to be taken on a tax return, in order for those tax positions to be recognized in the financial statements. When necessary, the Organization accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. The Organization does not expect that unrecognized tax benefits arising from tax positions will change significantly within the next 12 months.

3. Contributions Receivable

At December 31, 2016, contributions receivable are expected to be realized in the following periods:

In one year or less	\$ 402,236
Between one year and five years	<u>334,000</u>
	736,236
Less: discount at 3.75%	<u>(12,072)</u>
	<u>\$ 724,164</u>

4. Annuity Contract

The Organization has entered into a fixed annuity contract with Massachusetts Mutual Life Insurance Company (Mass Mutual). The Organization's contract investment balance is credited with earnings based upon contractually determined interest rates, and is charged for withdrawals and administrative expenses. Mass Mutual establishes an effective annual interest rate. In no event will such effective annual interest rate be less than the minimum interest rate as defined by the contract. The annuity contract is included in the statement of financial position at contract value as reported by Mass Mutual, which approximates fair value. There are no reserves against contract value for credit risk of the issuer or otherwise.

The minimum guaranteed interest rate is 1.75%. For the year ended December 31, 2016, the average yield was 1.81%.

The contract did not specify the circumstances under which the issuer may terminate the contract other than a written notice to the contract holder 30 days prior to the intended termination date. Currently, management believes that the occurrence of an event that would cause the Organization to receive less than contract value is not probable.

The Progeria Research Foundation, Inc.

Notes to Financial Statements

For the Year Ended December 31, 2016

5. Investments

A comparison of the actual costs and fair values of investments at December 31, 2016 is as follows:

	<u>Cost</u>	<u>Fair Value</u>	<u>Unrealized Gains (Losses)</u>
Investments held at fair value:			
Certificates of deposit	\$ 3,047,454	\$ 3,047,454	\$ -
Annuity contract	<u>208,734</u>	<u>208,734</u>	<u>-</u>
	<u>\$ 3,256,188</u>	<u>\$ 3,256,188</u>	<u>\$ -</u>

Investment income totaling \$50,942 for the year ended December 31, 2016 represented interest and dividends. There was no unrealized or realized gains or losses during the year ended December 31, 2016.

6. Fair Value Investments

The following table sets forth by level, within the fair value hierarchy, the Organization's investments at fair value on a recurring basis at December 31, 2016:

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Fixed income securities:				
Certificates of deposit	\$ -	\$ 3,047,454	\$ -	\$ 3,047,454
Annuity contract	<u>-</u>	<u>-</u>	<u>208,734</u>	<u>208,734</u>
	<u>\$ -</u>	<u>\$ 3,047,454</u>	<u>\$ 208,734</u>	<u>\$ 3,256,188</u>

The following table summarizes the changes in the carrying value associated with Level 3 financial instruments carried at fair value during the year ended December 31, 2016:

Balance at beginning of year	\$ 204,983
Investment income, net	<u>3,751</u>
Balance at end of year	<u>\$ 208,734</u>

7. Property and Equipment

Property and equipment at December 31, 2016 consisted of the following:

Furniture and equipment	\$ 42,874
Leasehold improvements	<u>7,132</u>
	50,006
Less: accumulated depreciation	<u>(29,991)</u>
	<u>\$ 20,015</u>

Depreciation expense totaled \$6,513 for the year ended December 31, 2016.

The Progeria Research Foundation, Inc.

Notes to Financial Statements

For the Year Ended December 31, 2016

8. Patents

Patent costs for the development of a Farnesyltransferase inhibitors (FTIs) drug treatment for children with Progeria totaled \$113,868, net of accumulated amortization of \$16,133, at December 31, 2016. Amortization expense totaled \$6,972 for the year ended December 31, 2016. Amortization expense for the years ending December 31, 2017 through 2021 will be \$7,202 per annum and \$61,725 thereafter.

Amortization expense for the years ending December 31st are as follows:

2017	\$ 7,202
2018	7,202
2019	7,202
2020	7,202
2021	7,202
Thereafter	<u>61,725</u>
	<u>\$ 97,735</u>

9. Net assets

Temporarily restricted net assets at December 31, 2016 have been restricted by donors as follows:

Research Grants	\$ 56,250
Timing	<u>678,928</u>
	<u>\$ 735,178</u>

10. Retirement Plans

During the year ended December, 31, 2016 the Organization began sponsoring a retirement plan under Section 401(k) of the Internal Revenue Code covering substantially all employees. The Organization may elect to provide a discretionary employer matching contribution. For the year ended December 31, 2016, the Organization did not make an employer matching contribution.

11. Commitments

Office and Equipment Leases

The Organization leases office space under a non-cancelable operating lease, which expires in December 2017. The lease provides for annual increases in base rent amounts and an option to renew for an additional five-year term. Rent expense under this office lease totaled \$36,000 for the year ended December 31, 2016.

The Organization leases office equipment under two non-cancelable operating leases, which expire at various times through October 2019. Rent expense under these equipment leases totaled \$11,465 for the year ended December 31, 2016.

Future minimum lease payments required under these leases for the years ending December 31st are as follows:

2017	\$ 47,856
2018	7,304
2019	<u>4,940</u>
	<u>\$ 60,100</u>

The Progeria Research Foundation, Inc.

Notes to Financial Statements

For the Year Ended December 31, 2016

11. Commitments...continued

Research Grants and Other Assistance

The Organization provides research grants and other assistance to qualified doctors and scientists to conduct research for the treatment and cure for Hutchinson-Gilford Progeria Syndrome and its aging-related disorders, including heart disease. These grants are awarded bi-annually and are subject to certain reporting and other requirements in accordance with the specific grant applications, which payment by the Organization may be withheld until the requirements have been met by the researcher. Payments under the grants are accrued quarterly in the accompanying statement of financial position.

Future payments committed to under these research grants for the years ending December 31st are as follows:

2017	\$ 552,523
2018	360,750
2019	<u>59,375</u>
	<u>\$ 972,648</u>

12. Concentrations of Credit Risk

Financial instruments that potentially subject the Organization to concentrations of credit risk consist principally of cash and cash equivalents and contributions receivable.

The Organization maintains its cash and cash equivalents in bank deposit accounts, which at times may exceed federally insured limits. The Organization has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents.

Contributions receivable due from one donor represented 90% of the outstanding balance at December 31, 2016.

For the year ended December 31, 2016, one donor represented 30% total support and revenue. This is the result of a unique circumstance, a one-time significant donation from an individual donor.

13. Subsequent Events

The Organization has evaluated subsequent events for potential disclosure or recognition through August 16, 2017, the date the financial statements were available to be issued.